NO965627L - Nytt cytokin betegnet lerk-5 - Google Patents

Nytt cytokin betegnet lerk-5

Info

Publication number
NO965627L
NO965627L NO965627A NO965627A NO965627L NO 965627 L NO965627 L NO 965627L NO 965627 A NO965627 A NO 965627A NO 965627 A NO965627 A NO 965627A NO 965627 L NO965627 L NO 965627L
Authority
NO
Norway
Prior art keywords
larch
lerk
new cytokine
cytokine designated
designated
Prior art date
Application number
NO965627A
Other languages
English (en)
Norwegian (no)
Other versions
NO965627D0 (no
Inventor
Douglas Pat Cerretti
Pranhitha Reddy
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23037772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO965627(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of NO965627D0 publication Critical patent/NO965627D0/no
Publication of NO965627L publication Critical patent/NO965627L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • External Artificial Organs (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
NO965627A 1994-07-08 1996-12-30 Nytt cytokin betegnet lerk-5 NO965627L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/271,948 US6303769B1 (en) 1994-07-08 1994-07-08 Lerk-5 dna
PCT/US1995/008534 WO1996001839A1 (en) 1994-07-08 1995-07-06 Novel cytokine designated lerk-5

Publications (2)

Publication Number Publication Date
NO965627D0 NO965627D0 (no) 1996-12-30
NO965627L true NO965627L (no) 1997-03-07

Family

ID=23037772

Family Applications (1)

Application Number Title Priority Date Filing Date
NO965627A NO965627L (no) 1994-07-08 1996-12-30 Nytt cytokin betegnet lerk-5

Country Status (14)

Country Link
US (4) US6303769B1 (de)
EP (1) EP0770088B1 (de)
JP (1) JPH10502810A (de)
AT (1) ATE286907T1 (de)
AU (1) AU684988B2 (de)
CA (1) CA2194299A1 (de)
DE (1) DE69533923T2 (de)
DK (1) DK0770088T3 (de)
ES (1) ES2236710T3 (de)
FI (1) FI965297A7 (de)
NO (1) NO965627L (de)
NZ (1) NZ290253A (de)
PT (1) PT770088E (de)
WO (1) WO1996001839A1 (de)

Families Citing this family (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5864020A (en) * 1994-07-20 1999-01-26 Genentech, Inc. HTK ligand
DE69635667T2 (de) * 1995-10-25 2006-09-07 Regeneron Pharmaceuticals, Inc. Biologisch aktive liganden der eph familie
AU2538697A (en) * 1996-03-21 1997-10-22 Immunex Corporation Cytokine designated lerk-8
CA2259157A1 (en) 1996-07-05 1998-01-15 Mount Sinai Hospital Corporation Oligomerized receptors which affect pathways regulated by transmembrane ligands for elk-related receptor tyrosine kinases
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
US6864227B1 (en) 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
ATE318095T1 (de) 1999-12-13 2006-03-15 J R Crompton Ltd Aufgussbeutel und entsprechende herstellungsmaterialien
GB0002339D0 (en) 2000-02-02 2000-03-22 Crompton J R Plc Beverage infusion packages and materials therefor
WO2002026827A1 (en) * 2000-09-29 2002-04-04 Novartis Ag Extracellular polypeptides of eph b receptors and ephrin b ligands and the corresponding nucleic acid molecules
US20040110150A1 (en) * 2002-12-10 2004-06-10 Isis Pharmaceuticals Inc. Modulation of Ephrin-B2 expression
JP2006507256A (ja) 2002-09-24 2006-03-02 ザ バーナム インスティチュート Ｅｐｈ受容体活性を調節する新規薬剤
US7381410B2 (en) * 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
EP1605961A4 (de) * 2003-03-12 2009-11-11 Vasgene Therapeutics Inc Polypeptid-verbindungen zur hemmung der angiogenese und des tumorwachstums
EA015363B1 (ru) 2003-07-18 2011-06-30 Эмджен Инк. Агенты, специфически связывающие фактор роста гепатоцитов, и их применение
WO2005090406A2 (en) * 2004-03-12 2005-09-29 Vasgene Therapeutics, Inc. Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
KR20120123619A (ko) 2004-03-12 2012-11-08 바스진 테라퓨틱스, 인크. 혈관형성 및 종양 성장을 억제하기 위한 폴리펩티드 화합물
WO2006034455A2 (en) * 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
AU2005286663A1 (en) * 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Compositions and methods for detecting and treating tumors
WO2006081418A2 (en) 2005-01-27 2006-08-03 The Burnham Institute Ephb receptor-binding peptides
US7906116B2 (en) 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
EP1937291A2 (de) * 2005-09-23 2008-07-02 Vasgene Therapeutics, Inc. Verwendung von mitteln gegen ephrin2 zur behandlung oder prävention von virusinfektionen
US20090270315A1 (en) * 2005-10-05 2009-10-29 Aqumen Biopharmaceuticals K.K. Method of inhibiting angiogenesis by using ephrin b2
RU2451031C2 (ru) 2006-01-20 2012-05-20 Дженентек, Инк. Антитела к эфрину в2 и способы их применения
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
CA2676173A1 (en) 2007-02-16 2008-08-28 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
CN102083861B (zh) * 2007-08-13 2016-04-13 瓦斯基因治疗公司 使用结合EphB4的人源化抗体的癌症治疗
JP5718640B2 (ja) 2007-08-21 2015-05-13 アムジエン・インコーポレーテツド ヒトｃ−ｆｍｓ抗原結合性タンパク質
PL3912643T3 (pl) 2009-02-13 2023-01-23 Immunomedics Inc. Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo
WO2011034660A1 (en) 2009-09-16 2011-03-24 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
IN2012DN03354A (de) 2009-12-02 2015-10-23 Immunomedics Inc
KR101606250B1 (ko) 2011-03-23 2016-03-24 암젠 인크 Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
WO2013025939A2 (en) 2011-08-16 2013-02-21 Indiana University Research And Technology Corporation Compounds and methods for treating cancer by inhibiting the urokinase receptor
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
AU2013302696B9 (en) 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
EP2890696A1 (de) 2012-08-29 2015-07-08 Amgen, Inc. Quinazolinonverbindungen und derivate davon
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
CN107753954A (zh) 2012-12-13 2018-03-06 免疫医疗公司 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
EP3712166A1 (de) 2013-09-05 2020-09-23 Amgen Inc. Fc-haltige moleküle mit vorhersagbaren, konsistenten und reproduzierbaren glycoformprofilen
ES2978993T3 (es) 2014-02-21 2024-09-23 Ibc Pharmaceuticals Inc Terapia de enfermedades mediante la inducción de la respuesta inmunitaria a las células que expresan Trop-2
CA2935748A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
WO2015175861A1 (en) 2014-05-16 2015-11-19 Amgen Inc. Assay for detecting th1 and th2 cell populations
US9580495B2 (en) 2014-06-24 2017-02-28 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
PL3204018T3 (pl) 2014-10-07 2022-01-03 Immunomedics, Inc. Neoadiuwantowe zastosowanie koniugatów przeciwciało-lek
EP3286224A4 (de) 2015-04-22 2018-11-14 Immunomedics, Inc. Isolierung, detektion, diagnose und/oder charakterisierung von zirkulierenden trop-2-positiven krebszellen
PT3313443T (pt) 2015-06-25 2023-08-30 Immunomedics Inc Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro
PL3316885T3 (pl) 2015-07-01 2021-12-06 Immunomedics, Inc. Immunokoniugaty przeciwciało-sn-38 z linkerem cl2a
MX2018010851A (es) 2016-03-08 2019-02-07 Janssen Biotech Inc Anticuerpos de gitr, métodos, y usos.
EP3484499A4 (de) 2016-07-14 2020-05-13 Scholar Rock, Inc. Tgfb-antikörper, verfahren und verwendungen
CR20190338A (es) 2016-12-22 2019-09-09 Amgen Inc Inhibidores de kras g12c y métodos para su uso
AU2018235928B2 (en) 2017-03-14 2023-09-21 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
UA127968C2 (uk) 2017-05-22 2024-02-28 Емджен Інк. Інгібітори g12c kras і способи їх застосування
US10640504B2 (en) 2017-09-08 2020-05-05 Amgen Inc. Inhibitors of KRAS G12C and methods of using the same
US12325737B2 (en) 2018-03-26 2025-06-10 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
MX2020010836A (es) 2018-05-04 2021-01-08 Amgen Inc Inhibidores de kras g12c y métodos para su uso.
EP3788053B1 (de) 2018-05-04 2024-07-10 Amgen Inc. Kras-g12c-inhibitoren und verfahren zu deren verwendung
WO2019217691A1 (en) 2018-05-10 2019-11-14 Amgen Inc. Kras g12c inhibitors for the treatment of cancer
WO2019232419A1 (en) 2018-06-01 2019-12-05 Amgen Inc. Kras g12c inhibitors and methods of using the same
AU2019284472B2 (en) 2018-06-11 2024-05-30 Amgen Inc. KRAS G12C inhibitors for treating cancer
JP7369719B2 (ja) 2018-06-12 2023-10-26 アムジエン・インコーポレーテツド ＫＲａｓ Ｇ１２Ｃ阻害剤及びそれを使用する方法
JP7516029B2 (ja) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
JP7454572B2 (ja) 2018-11-19 2024-03-22 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤及びその使用方法
IL283639B2 (en) 2018-12-20 2024-06-01 Amgen Inc Kif18a inhibitors
AU2019404576B2 (en) 2018-12-20 2025-07-17 Amgen Inc. Heteroaryl amides useful as KIF18A inhibitors
MA54550A (fr) 2018-12-20 2022-03-30 Amgen Inc Inhibiteurs de kif18a
AU2019401495B2 (en) 2018-12-20 2025-06-26 Amgen Inc. Heteroaryl amides useful as KIF18A inhibitors
WO2020180768A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
US20230096028A1 (en) 2019-03-01 2023-03-30 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
EP3738593A1 (de) 2019-05-14 2020-11-18 Amgen, Inc Dosierung von kras-inhibitor zur behandlung von krebserkrankungen
EP3972973A1 (de) 2019-05-21 2022-03-30 Amgen Inc. Festkörperformen
US20220289724A1 (en) 2019-08-02 2022-09-15 Amgen Inc. Kif18a inhibitors
AU2020325115B2 (en) 2019-08-02 2026-03-12 Amgen Inc. Pyridine derivatives as KIF18A inhibitors
JP7699100B2 (ja) 2019-08-02 2025-06-26 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤
MX428368B (es) 2019-08-02 2025-11-13 Amgen Inc Inhibidores de kif18a
US20220402916A1 (en) 2019-09-18 2022-12-22 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12c mutant
KR20220069982A (ko) 2019-09-26 2022-05-27 암젠 인크 항체 조성물의 생산 방법
EP4045515A4 (de) 2019-10-18 2023-10-18 The Regents Of The University Of Michigan Biomaterialsensorsysteme
AU2020369569B2 (en) 2019-10-24 2026-06-18 Amgen Inc. Pyridopyrimidine derivatives useful as KRAS G12C and KRAS G12D inhibitors in the treatment of cancer
MD4051678T2 (en) 2019-10-28 2026-07-31 Merck Sharp & Dohme Llc Small molecule inhibitors of the KRAS G12C mutant
WO2021085653A1 (en) 2019-10-31 2021-05-06 Taiho Pharmaceutical Co., Ltd. 4-aminobut-2-enamide derivatives and salts thereof
WO2021091956A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
MX2022005359A (es) 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
CN121471132A (zh) 2019-11-04 2026-02-06 锐新医药公司 Ras抑制剂
PH12022551102A1 (en) 2019-11-08 2023-11-20 Revolution Medicines Inc Bicyclic heteroaryl compounds and uses thereof
EP4700030A3 (de) 2019-11-14 2026-03-18 Amgen, Inc. Verbesserte synthese einer kras-g12c-inhibitorverbindung
CA3161156A1 (en) 2019-11-14 2021-05-20 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
CN114980976A (zh) 2019-11-27 2022-08-30 锐新医药公司 共价ras抑制剂及其用途
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
WO2021126799A1 (en) 2019-12-18 2021-06-24 Merck Sharp & Dohme Corp. Macrocyclic peptides as potent inhibitors of k-ras g12d mutant
CA3163703A1 (en) 2020-01-07 2021-07-15 Steve Kelsey Shp2 inhibitor dosing and methods of treating cancer
US12702658B2 (en) 2020-04-24 2026-08-11 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C
WO2021215544A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
WO2021247892A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
CN115916194A (zh) 2020-06-18 2023-04-04 锐新医药公司 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法
TW202216151A (zh) 2020-07-15 2022-05-01 日商大鵬藥品工業股份有限公司 含有使用於腫瘤之治療之嘧啶化合物之組合
EP4208261A1 (de) 2020-09-03 2023-07-12 Revolution Medicines, Inc. Verwendung von sos1-inhibitoren zur behandlung von malignitäten mit shp2-mutationen
IL301298A (en) 2020-09-15 2023-05-01 Revolution Medicines Inc Indole derivatives as RAS inhibitors in cancer therapy
US20240043501A1 (en) 2020-10-15 2024-02-08 Amgen Inc. Relative unpaired glycans in antibody production methods
AU2021409816A1 (en) 2020-12-22 2023-07-06 Qilu Regor Therapeutics Inc. Sos1 inhibitors and uses thereof
JP2024510435A (ja) 2021-03-18 2024-03-07 シージェン インコーポレイテッド 生体活性化合物の内部移行複合体からの選択的薬物放出
WO2022235866A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
PE20240088A1 (es) 2021-05-05 2024-01-16 Revolution Medicines Inc Inhibidores de ras
IL308195A (en) 2021-05-05 2024-01-01 Revolution Medicines Inc RAS inhibitors for cancer treatment
EP4342497A1 (de) 2021-05-10 2024-03-27 Kawasaki Institute of Industrial Promotion Antikörper mit reduzierter bindungsaffinität für antigen
CN117769554A (zh) 2021-05-28 2024-03-26 大鹏药品工业株式会社 Kras突变蛋白的小分子抑制剂
AU2022289365A1 (en) 2021-06-07 2023-12-14 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
JP2024537100A (ja) 2021-10-05 2024-10-10 アムジエン・インコーポレーテツド Ｆｃガンマ受容体ＩＩ結合、及びグリカン含量
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
US20240294548A1 (en) 2021-10-12 2024-09-05 Peloton Therapeutics Inc. Tricyclic sultams and sulfamides as antitumor agents
TW202340214A (zh) 2021-12-17 2023-10-16 美商健臻公司 做為shp2抑制劑之吡唑并吡𠯤化合物
EP4227307A1 (de) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazinverbindungen als shp2-inhibitoren
KR20240156373A (ko) 2022-03-07 2024-10-29 암젠 인크 4-메틸-2-프로판-2-일-피리딘-3-카르보니트릴의 제조 방법
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
EP4536364A1 (de) 2022-06-10 2025-04-16 Revolution Medicines, Inc. Makrocyclische ras-inhibitoren
IL320217A (en) 2022-10-14 2025-06-01 Black Diamond Therapeutics Inc Methods for treating cancer using isoquinoline or 6-azaquinoline derivatives
CN121487738A (zh) 2023-03-30 2026-02-06 锐新医药公司 诱导ras gtp水解的组合物和其用途
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
CN121487951A (zh) 2023-04-07 2026-02-06 锐新医药公司 大环ras抑制剂
AU2024251341A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of a ras inhibitor
EP4695261A1 (de) 2023-04-14 2026-02-18 Revolution Medicines, Inc. Kristalline formen von ras-inhibitoren, zusammensetzungen damit und verfahren zur verwendung davon
JP2026516670A (ja) 2023-04-20 2026-05-26 アムジエン・インコーポレーテツド 相対的な不対グリカン含有量を決定する方法
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024325342A1 (en) 2023-08-14 2026-02-26 Amgen Inc. Methods for reducing yellow color
KR20260042550A (ko) 2023-08-24 2026-03-31 다이호야쿠힌고교 가부시키가이샤 세다주리딘 및 아자시티딘의 고정 용량 조합물
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
KR20260096846A (ko) 2023-10-20 2026-06-24 머크 샤프 앤드 돔 엘엘씨 Kras 단백질의 소분자 억제제
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
AU2024404879A1 (en) 2023-12-22 2026-06-25 Regor Pharmaceuticals, Inc. Sos1 inhibitors and uses thereof
US20250295801A1 (en) 2024-03-21 2025-09-25 Seagen Inc. Cd25 antibodies, antibody drug conjugates, and uses thereof
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090253A1 (en) 2024-10-23 2026-04-30 Amgen Inc. Methods of determining glycan pairing content
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161671A1 (en) 2025-01-23 2026-07-30 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5134121A (en) 1988-03-28 1992-07-28 Regents Of The University Of California Nerve growth factor peptides
IL95511A (en) 1989-08-30 2000-10-31 Max Planck Gesellschaft Neurotrophin-3 a novel neurotrophic factor related to nerve growth and brain derived neurotrophic factor
IE911318A1 (en) 1990-04-23 1991-10-23 Yeda Res & Dev Use of a tumor necrosis factor for facilitating nerve¹regeneration
JPH06504667A (ja) 1990-10-16 1994-06-02 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン 炎症性反応生起に関連するサイトカイン−誘起マーカー
ES2134804T3 (es) 1991-04-19 1999-10-16 Childrens Medical Center Uso de un compuesto generador de oxido nitrico para prevenir daño neuronal.
ATE278019T1 (de) 1991-06-21 2004-10-15 Inst Medical W & E Hall Neuartige rezeptor-typ tyrosinkinase und deren verwendung
PT669929E (pt) 1992-11-13 2007-04-30 Immunex Corp Ligando de elk, uma citoquina
FI952328A7 (fi) 1992-11-13 1995-07-10 Amgen Inc eck-respetorin lignandeja
JPH06262882A (ja) 1993-03-12 1994-09-20 Dainippon Printing Co Ltd 香り入りカード付き帳票
DE9305552U1 (de) 1993-04-16 1993-06-03 MAN Roland Druckmaschinen AG, 6050 Offenbach Einrichtung zum Inline-Beschichten von Bedruckstoffen in Offsetdruckmaschinen
US5516658A (en) 1993-08-20 1996-05-14 Immunex Corporation DNA encoding cytokines that bind the cell surface receptor hek
US5864020A (en) * 1994-07-20 1999-01-26 Genentech, Inc. HTK ligand
WO1996011212A1 (en) * 1994-10-07 1996-04-18 Asahi Kasei Kogyo Kabushiki Kaisha Novel receptor-type tyrosine kinase ligand
JPH08188596A (ja) * 1994-10-19 1996-07-23 Asahi Chem Ind Co Ltd リセプター型チロシンキナーゼの新規なリガンド

Also Published As

Publication number Publication date
DK0770088T3 (da) 2005-05-30
US6303769B1 (en) 2001-10-16
PT770088E (pt) 2005-04-29
EP0770088A1 (de) 1997-05-02
DE69533923D1 (de) 2005-02-17
NO965627D0 (no) 1996-12-30
ES2236710T3 (es) 2005-07-16
US6492140B2 (en) 2002-12-10
FI965297L (fi) 1997-03-07
CA2194299A1 (en) 1996-01-25
US6479459B1 (en) 2002-11-12
NZ290253A (en) 1998-02-26
WO1996001839A1 (en) 1996-01-25
DE69533923T2 (de) 2006-01-12
AU684988B2 (en) 1998-01-08
JPH10502810A (ja) 1998-03-17
EP0770088B1 (de) 2005-01-12
ATE286907T1 (de) 2005-01-15
US6596852B2 (en) 2003-07-22
US20020103358A1 (en) 2002-08-01
FI965297A0 (fi) 1996-12-31
EP0770088A4 (de) 1999-10-13
US20010009768A1 (en) 2001-07-26
AU3094095A (en) 1996-02-09
FI965297A7 (fi) 1997-03-07

Similar Documents

Publication Publication Date Title
FI965297A0 (fi) Uusi LERK-5:ksi nimetty sytokiini
NO960652L (no) Cytokiner som binder celleoverflatereseptoren hek
ATE350386T1 (de) Elk ligand, ein cytokin
ATE98992T1 (de) Klonierung und expression von htlv-iii dns.
DK582481A (da) Chimaerisk polypeptid,fremgangsmaade til dets fremstilling,kloningsmedium og mikrobielle transformanter til anvendelse ved fremgangsmaaden samt fremgangsmaade til fremstilling af humant insulin
MX9202970A (es) Secuencia adn, moleculas adn, y proceso para obtener un polipeptido.
DK517986A (da) Dna-sekvenser, rekombinant-dna-molekyler og fremgangsmaade til fremstilling af mueller-inhiberende stof-lignende polypeptider
FI821466A7 (fi) Bacillus-kloonausvektorit, yhdistelmä- DNA-molekyylit, niiden transformoimat Bacillus-isännät sekä menetelmätvieraiden DNA- sekvenssien ekspressiota varten sekä näiden koodaamien polypeptidien tuottamiseksi.
DK1009832T3 (da) Cytokin betegnet LERK-6
DK298689D0 (da) Fremgangsmaade til konservering af fodermaterialer, og additiv til anvendelse ved fremgangsmaaden
NO971378L (no) Cytokin betegnet LERK-6
AU590861B2 (en) New human lymphotoxin (TNF-beta) polypeptides their prepartion and use
DE3686473D1 (de) Cardiotonische thiazolone.
ZA95968B (en) Interferon alpha/beta binding protein its preparation and use
MX9700213A (es) Citocina novedosa designada como lerk-5.
NO984233L (no) Cytokin kalt lerk-8
Yoshimura et al. Design of microstructure in zirconia toughened ceramics
Laing REFRACTORIES AND KILN CARS- DESIGN AND SELECTION CONSIDERATIONS
Xia The TL dating of Mao Pagoda in Qingpu County
TATAREK et al. BREAKING RESISTANCE OF BRITTLE MATERIALS AT HIGH TEMPERATURE GRADIENTS
ATE386119T1 (de) Vier-helix bündelprotein zsig81
Hagedorn Basics of Linear Elastic or Elastic--Plastic Fracture Mechanics
Sarin Forthcoming Meeting
DE3688974D1 (de) Expressionssysteme zur überproduktion gewünschter proteine.
WO2002020567A3 (en) Mammalian cystatin-8 and its use to inhibit cancer procoagulant protein

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application